ReviewNeuro-oncology advances2026
Applications of transcranial focused ultrasound for primary brain tumors.
Review in Neuro-oncology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial.The Lancet. Oncology · 2025Trial
- Focused ultrasound for brain metastases.Neuro-oncology advances · 2026Review
- Acoustic emissions dose and spatial control of blood-brain barrier opening with focused ultrasound.Device · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals diagnosed with primary brain tumors (PBTs) experience major morbidity and mortality, compounded by the risks associated with standard-of-care brain-directed therapeutic approaches. Recurrence remains inevitable in patients with high-grade gliomas (HGG), due to their brain-infiltrative growth hindering surgical removal, immunosuppressive tumor-microenvironment, dynamic disease evolution from their high cellular and molecular heterogeneity, and multi-faceted challenges to brain drug delivery, primarily stemming from the blood-brain barrier (BBB). This expert narrative review describes the current state of transcranial focused ultrasound (FUS), and its multi-modal applications for PBTs, including delivery of therapeutic agents and sono-liquid biopsy (via BBB opening), immunomodulation, radio-sensitization, and direct destruction of tumor cells/tissue via thermoablation, histotripsy, and sonodynamic therapy. BBB opening-based approaches have the most promising clinical evidence so far, warranting randomized comparative evalutions. Further translation will require standardized FUS treatment protocols, translational investigations nested into trials, coordinated global efforts, strategic trial design incorporating methodological advances, and implementation approaches enabling broader participation. Worldwide efforts to advance FUS will be aided by ongoing device evolution, support from professional societies, and the development of FUS research consortia (like ReFOCUSED). FUS applications open a potential combinatorial path forward with systemic therapies for "adaptive theragnostic" tumor management, thus targeting the root causes of therapeutic failure for HGG patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.